[	O
The	O
clinical	O
and	O
laboratory	O
features	O
of	O
acute	B-Cancer
promyelocytic	I-Cancer
leukemia	I-Cancer
:	O
an	O
analysis	O
of	O
513	O
cases	O
]	O
.	O

OBJECTIVE	O
:	O

To	O
investigate	O
the	O
clinical	O
and	O
laboratory	O
features	O
of	O
acute	B-Cancer
promyelocytic	I-Cancer
leukemia	I-Cancer
(	O
APL	B-Cancer
)	O
.	O

METHODS	O
:	O

513	O
APL	B-Cancer
patients	O
in	O
the	O
last	O
two	O
decades	O
were	O
retrospectively	O
analyzed	O
in	O
this	O
research	O
.	O

We	O
investigated	O
the	O
clinical	O
features	O
including	O
age	O
,	O
sex	O
,	O
abnormality	O
of	O
peripheral	O
hemogram	O
before	O
treatment	O
,	O
therapeutic	O
effect	O
and	O
follow	O
-	O
up	O
and	O
laboratory	O
data	O
such	O
as	O
morphology	O
,	O
immunology	O
,	O
cytogenetics	O
and	O
molecular	O
biology	O
(	O
MICM	O
)	O
.	O

RESULTS	O
:	O

The	O
median	O
age	O
of	O
the	O
APL	B-Cancer
patients	O
was	O
33	O
years	O
old	O
and	O
the	O
ratio	O
of	O
male	O
and	O
female	O
was	O
1	O
.	O
21	O
:	O
1	O
.	O

Before	O
treatment	O
,	O
the	O
median	O
level	O
of	O
WBC	B-Cell
was	O
4	O
.	O
3	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
and	O
the	O
detection	O
rate	O
of	O
abnormal	O
promyelocyte	B-Cell
on	O
blood	B-Organism_substance
film	O
was	O
85	O
.	O
8	O
%	O
;	O
with	O
immunophenotypic	O
detection	O
,	O
the	O
expression	O
levels	O
of	O
CD117	O
,	O
CD34	O
,	O
HLA	O
-	O
DR	O
,	O
CD7	O
,	O
CD14	O
and	O
CD19	O
in	O
APL	B-Cancer
were	O
found	O
to	O
be	O
lower	O
and	O
the	O
expression	O
levels	O
of	O
CD2	O
,	O
CD33	O
and	O
MPO	O
higher	O
than	O
those	O
in	O
other	O
subtypes	O
of	O
acute	B-Cancer
myelocytic	I-Cancer
leukemia	I-Cancer
(	O
AML	B-Cancer
)	O
(	O
both	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Specific	O
abnormal	O
chromosome	B-Cellular_component
t	O
(	O
15	O
;	O
17	O
)	O
was	O
detected	O
in	O
91	O
.	O
7	O
%	O
of	O
the	O
patients	O
,	O
of	O
whom	O
75	O
.	O
9	O
%	O
had	O
standard	O
translocation	O
of	O
t	O
(	O
15	O
;	O
17	O
)	O
,	O
being	O
the	O
most	O
common	O
one	O
and	O
15	O
.	O
8	O
%	O
of	O
the	O
patients	O
had	O
t	O
(	O
15	O
;	O
17	O
)	O
with	O
additional	O
abnormal	O
chromosome	B-Cellular_component
.	O

There	O
was	O
only	O
7	O
.	O
5	O
%	O
of	O
the	O
patients	O
with	O
normal	O
karyotype	O
.	O

However	O
,	O
the	O
presence	O
of	O
both	O
simple	O
translocation	O
and	O
complex	O
translocation	O
was	O
seldom	O
seen	O
.	O

With	O
molecular	O
biological	O
detection	O
,	O
PML	O
/	O
RARalpha	O
fusion	O
gene	O
positive	O
rate	O
was	O
99	O
.	O
6	O
%	O
.	O

In	O
a	O
relatively	O
long	O
clinical	O
follow	O
-	O
up	O
,	O
we	O
found	O
that	O
the	O
complete	O
remission	O
(	O
CR	O
)	O
rate	O
in	O
APL	B-Cancer
patients	O
was	O
84	O
.	O
7	O
%	O
,	O
incidence	O
of	O
DIC	O
was	O
13	O
.	O
4	O
%	O
and	O
five	O
-	O
year	O
survival	O
rate	O
was	O
30	O
.	O
7	O
%	O
.	O

The	O
median	O
count	O
of	O
WBC	B-Cell
in	O
CR	O
group	O
was	O
lower	O
than	O
that	O
non	O
-	O
remission	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
on	O
expressions	O
of	O
CD34	O
and	O
CD2	O
and	O
changes	O
of	O
cytogenetics	O
between	O
the	O
two	O
groups	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O

Comprehensive	O
evaluation	O
of	O
MICM	O
could	O
be	O
of	O
important	O
significance	O
in	O
the	O
diagnosis	O
and	O
prognosis	O
judgment	O
for	O
APL	B-Cancer
patients	O
.	O

The	O
CR	O
rate	O
in	O
these	O
patients	O
with	O
high	O
WBC	B-Cell
count	O
was	O
considerable	O
low	O
.	O

